GCG and metabolic dysfunction-associated steatotic liver disease: Semaglutide, a GLP1-RA offered in subcutaneous and oral formulations, holds promise as a treatment for NAFLD due to its multifaceted mechanisms of action, rendering it a promising treatment for the disease [28].